Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Rezurock on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Rezurock (belumosudil) is a kinase inhibitor approved by the FDA for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Rezurock inhibits Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway involved in the abnormal immune activity and tissue fibrosis that characterize chronic GVHD, helping reduce inflammation and improve symptoms in affected patients.
Rezurock is intended for patients with chronic GVHD, a serious complication of allogeneic stem cell transplantation, whose disease has not responded to at least two prior systemic treatments.
The recommended dose of Rezurock is 200 mg taken orally once daily with food, continued until GVHD progression requires a new systemic therapy.
Rezurock does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Rezurock may cause fetal harm. Effective contraception should be used during treatment and for one week after the final dose. Breastfeeding is not recommended during treatment and for one week after the final dose.
Liver function should be monitored monthly during treatment, as hepatotoxicity has been reported.
Rezurock has significant interactions with BCRP, OATP1B1, CYP, and P-glycoprotein substrates. All concomitant medicines should be reviewed by the treating physician before starting therapy.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Rezurock is manufactured and marketed by Kadmon Pharmaceuticals, a Sanofi company. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating transplant physician or hematologist confirming chronic GVHD diagnosis and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for chronic GVHD, Rezurock is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Rezurock directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Rezurock should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Rezurock through NPP's regulated import pathway, with transplant and GVHD specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support transplant care coordination and documentation for Rezurock access.
Delhi's major hospitals assist patients with prescription support and documentation for Rezurock.
Bangalore's specialist network offers access coordination for eligible chronic GVHD patients seeking Rezurock.
Chennai-based transplant specialists coordinate Rezurock access alongside comprehensive GVHD care.
Hyderabad's care institutions support patients pursuing Rezurock therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Rezurock.
Pune-based specialists assist with prescription support and Rezurock treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Rezurock.
Kochi's specialist units assist patients with the documentation needed for Rezurock access.
Chandigarh's care centers support Rezurock treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Rezurock access process.
Lucknow-based centers assist patients pursuing Rezurock therapy.
Bhubaneswar's institutions support access to Rezurock for eligible patients.
Guwahati's specialists help coordinate Rezurock access for patients across the Northeast.
Patients in other cities across India can also access Rezurock through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
